NCT01520779已完成不适用
Risk Factors for Recurrence of Hepatocellular Carcinoma After Radiofrequency Ablation
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 99
- 试验地点
- 1
- 主要终点
- Recurrence of hepatocellular carcinoma
研究概览
简要总结
analysis of the risk factors of intra-hepatic distant recurrence (IDR) of hepatocellular carcinoma within 1 year after radiofrequency ablation.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Proved diagnosis of HCC according to AASLD practice guidelines (Bruix and Sherman, 2005).
- •Patients underwent RFA for HCC with BCLC (The Barcelona-Clinic- Liver-Cancer staging system) stage A (Bruix and Sherman, 2005) with no eligibility or ability to do transplantation or resection.
- •Patients should be followed-up for more than 12 months to exclude early recurrence i.e. recurrence within 1 year.
- •Patients with INR < 1.5 or prothrombin concentration > 50%.
- •Platelet count > 50000 cell/mm3.
排除标准
- •Presence of extra-hepatic metastasis or gross vascular invasion.
- •Child class C patients.
- •Follow up period of less than 12 months.
结局指标
主要结局
Recurrence of hepatocellular carcinoma
时间窗: 1 year
次要结局
未报告次要终点
研究者
Iman Fawzy Montasser
Lecturer of tropical medicine , Ain Shams university
Ain Shams University
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Postoperative Adjuvant Immunotherapy for Hepatocellular Carcinoma: Risk Factor Analysis and Prognostic ModellingAdjuvant ImmunotherapyCheckpoint InhibitorHepatocellular CarcinomaNCT06298123Chen Xiaoping304
Unknown
不适用
Incidence of de Novo Hepatocellular Carcinoma After Antiviral Agents for HCV.Antiviral Drug Adverse ReactionHepatitis CCirrhosisNCT03775798Austral University, Argentina2,200
已完成
不适用
Risk Factors of Hepatocellular Carcinomas Developed on Non-fibrotic Liver: Case-control Study (NoFlic Study)Hepatocellular CarcinomaNCT03852238University Hospital, Bordeaux283
招募中
不适用
Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNAHepatocellular Carcinoma ResectableNCT06157060Zhujiang Hospital255
招募中
不适用
Perioperative Risk of Immunotherapy Based Neoadjuvant and Conversion Therapy for Hepatocellular CarcinomaCarcinoma, HepatocellularImmunotherapyNCT06571396Qilu Hospital of Shandong University200